Role of TIM3 Pathway in Immune Pathogenesis and Targeted Therapy of Myelodysplastic Syndrome
10.3971/j.issn.1000-8578.2025.25.0396
- VernacularTitle:TIM3相关通路在骨髓增生异常综合征免疫发病机制及靶向治疗中的作用
- Author:
Xinyu GUO
1
;
Shunjie YU
2
;
Jinglian TAO
3
;
Yingshuai WANG
4
;
Xiaotong REN
1
;
Zhaoyun LIU
1
;
Rong FU
1
;
Zonghong SHAO
1
;
Lijuan LI
1
Author Information
1. Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
2. Department of Hematology, Peking University People's Hospital, Beijing 100044, China.
3. Center for Molecular Medicine, University of Georgia, Athens, GA 30602, America.
4. Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao 266005, China.
- Publication Type:SPECIALFEATURE
- Keywords:
TIM3;
Myelodysplastic syndrome;
Signaling pathway;
Immune checkpoints;
Immune escape;
Targeted therapy
- From:
Cancer Research on Prevention and Treatment
2025;52(9):731-735
- CountryChina
- Language:Chinese
-
Abstract:
Myelodysplastic syndrome (MDS), a myeloid tumor derived from the malignant clones of hematopoietic stem cells, has an annually increasing incidence. The contemporary research direction has shifted to analyzing the synergistic effect of immune surveillance collapse and abnormal bone marrow microenvironment in the pathological process of MDS. Against this backdrop, the immune checkpoint molecule TIM3 has emerged as a key target because of its persistently high expression on the surface of important immune cells such as T and NK cells. The abnormal activation of the TIM3 pathway is the mechanism by which solid tumors and hematological malignancies achieve immune escape and is a key hub in the formation of immune exhaustion phenotypes. This work integrates the original discoveries of our team with the latest international progress, systematically demonstrating the bidirectional regulatory network of TIM3 between the malignant clone proliferation of MDS and the immunosuppressive microenvironment. Integrating the evidence from emerging clinical trials allows us to consider the clinical significance of TIM3-targeted blocking for MDS, providing a transformative path to overcome the resistance of traditional treatments and marking a new chapter in the active immune reconstitution of MDS treatment.
